PR NEWSWIRE | The US Food and Drug Administration (FDA) has granted Orphan Drug Designation for PLG0206,  a first-in-class, broad-spectrum antibiotic peptide developed by Peptilogics.  PLG0206 is in development for the treatment of prosthetic joint infections (PJI), a rare life-threatening condition that may result from arthroplasty or joint replacement procedures. PLG0206 is funded by CARB-X.